Prognostic Study of Different HPV Virus Integration in Women With HSIL

Status: Recruiting
Location: See all (13) locations...
Intervention Type: Other
Study Type: Observational
SUMMARY

Human papillomavirus (HPV) is currently one of the most common sexually transmitted infections, according to its carcinogenicity is divided into high-risk genotypes and low-risk genotypes, research has confirmed that carcinogenic HPV type continuous infection leads to a higher incidence of condyloma acuminatum and cervical cancer, while increasing the oropharyngeal cancer, vaginal cancer and other related cancer risk. Based on clinical practice, the purpose of this study was to: 1) identify the correlation between HPV integration and the outcome of disease in HSIL women. 2) To determine the prognostic value of different HPV gene integration status in HSIL women. 3) To clarify the relationship between different HPV gene integration status and diversity of vaginal flora in HSIL women.

Eligibility
Participation Requirements
Sex: Female
Healthy Volunteers: f
View:

• Pathologically confirmed HSIL(CIN2, 3) in women or cervical carcinoma in situ or early invasive cancer;

• No surgical treatment or conization only;

• Obtain informed consent.

Locations
Other Locations
China
Fujian Maternity and Child Health Hospital
RECRUITING
Fuzhou
Longyan First Hospital
ACTIVE_NOT_RECRUITING
Longyan
Longyan People's Hospital
ACTIVE_NOT_RECRUITING
Longyan
Nanping Second Hospital
RECRUITING
Nanping
Mindong Hospital of Ningde City
RECRUITING
Ningde
Ningde City Hospital
ACTIVE_NOT_RECRUITING
Ningde
Affiliated Hospital of Putian University
ACTIVE_NOT_RECRUITING
Putian
Putian First Hospital
RECRUITING
Putian
Sanming Second Hospital
RECRUITING
Sanming
Shenzhen Maternity and child Healthcare Hospital
RECRUITING
Shenzhen
Shijiazhuang Obstetrics and Gynecology Hospital
ACTIVE_NOT_RECRUITING
Shijiazhuang
Affiliated Hospital of Tongji Medical College, Huazhong University of Science and Technology
ACTIVE_NOT_RECRUITING
Wuhan
Maternal and Child Health Hospital of Hubei Province
ACTIVE_NOT_RECRUITING
Wuhan
Contact Information
Primary
Binhua Dong
dbh18-jy@126.com
+86-591-87558732
Backup
Pengming Sun
sunfemy@hotmail.com
+86-591-87558732
Time Frame
Start Date: 2023-01-01
Estimated Completion Date: 2025-10-31
Participants
Target number of participants: 1000
Treatments
HSIL (CIN2,3) women or cervical carcinoma in situ or early invasive carcinoma confirmed by pathology
In this study, women with pathologically confirmed HSIL(CIN2, 3) or women with cervical carcinoma in situ or early invasive cancer will be included. All participants will have four follow-up visits at enrollment and at months 6, 12, and 24.
Sponsors
Leads: Fujian Maternity and Child Health Hospital

This content was sourced from clinicaltrials.gov